Tumor Biology

, Volume 35, Issue 4, pp 3087–3094 | Cite as

RETRACTED ARTICLE: Steroid receptor co-activator-3 promotes osteosarcoma progression through up-regulation of FoxM1

  • Shuo Geng
  • Xiaoyu Wang
  • Xiaoyan Xu
  • Hepeng Zhang
  • Yan Ma
  • Yunqi Zhang
  • Baoxin Li
  • Zhenggang Bi
  • Chenglin Yang
Research Article

Abstract

Increasing evidence suggests that the three homologous members of steroid receptor co-activator (SRC) family (SRC-1, SRC-2, and SRC-3) play key roles in enhancing cell proliferation in various human cancers, such as breast, prostate, and hepatocellular carcinoma. However, the function of SRC-3 in osteosarcoma remains largely unexplored. In the current study, we found that SRC-3, but not SRC-1 and SRC-2, was dramatically up-regulated in human osteosarcoma tissues, compared with adjacent normal tissues. To explore the functions of SRC-3 in osteosarcoma, in vitro studies were performed in MG63 and U2OS cells. SRC-3 overexpression promoted osteosarcoma cell proliferation, whereas knockdown of SRC-3 inhibits its proliferation. In support of these findings, we further demonstrated that SRC-3 up-regulated FoxM1 expression through co-activation of C/EBPγ. Together our results show that SRC-3 drives osteosarcoma progression and imply it as a therapeutic target to abrogate osteosarcoma.

Keywords

Osteosarcoma Transcription SRC-3 FoxM1 C/EBPγ 

Notes

Acknowledgments

This work was partially supported by National Natural Science Foundation of China (81271984), Research Fund for the Doctoral Program of Higher Education of China (20122307120036), Natural Science Foundation for Returnees of Heilongjiang Province of China (LC2012C11), Research Fund for Returnees of Education Department of Heilongjiang Province of China (1253HQ003), Research Fund of the First Affiliated Hospital of Harbin Medical University(2013LX01).

Conflicts of interest

None

Supplementary material

13277_2013_1406_Fig7_ESM.jpg (1 kb)
Supplementary Figure 1

Representative protein levels of SRC-3 were analyzed by western blot in normal tissues (N) or osteosarcoma tissues (OS). (JPEG 0 kb)

13277_2013_1406_MOESM1_ESM.tif (275 kb)
High resolution image (TIFF 275 kb)

References

  1. 1.
    Luo Y, Deng Z, Chen J. Pivotal regulatory network and genes in osteosarcoma. Arch Med Sci. 2013;9:569–75.CrossRefPubMedGoogle Scholar
  2. 2.
    Poos K, Smida J, Nathrath M, Maugg D, Baumhoer D, et al. How microRNA and transcription factor co-regulatory networks affect osteosarcoma cell proliferation. PLoS Comput Biol. 2013;9:e1003210.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Xu J, Wu RC, O'Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer. 2009;9:615–30.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Gojis O, Rudraraju B, Gudi M, Hogben K, Sousha S, et al. The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol. 2010;7:83–9.CrossRefPubMedGoogle Scholar
  5. 5.
    York B, Yu C, Sagen JV, Liu Z, Nikolai BC, et al. Reprogramming the posttranslational code of SRC-3 confers a switch in mammalian systems biology. Proc Natl Acad Sci U S A. 2010;107:11122–7.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    York B, O'Malley BW. Steroid receptor coactivator (SRC) family: masters of systems biology. J Biol Chem. 2010;285:38743–50.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Johnson AB, O'Malley BW. Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. Mol Cell Endocrinol. 2012;348:430–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Walsh CA, Qin L, Tien JC, Young LS, Xu J. The function of steroid receptor coactivator-1 in normal tissues and cancer. Int J Biol Sci. 2012;8:470–85.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    McBryan J, Theissen SM, Byrne C, Hughes E, Cocchiglia S, et al. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res. 2012;72:548–59.CrossRefPubMedGoogle Scholar
  10. 10.
    Agoulnik IU, Weigel NL. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol. 2008;617:245–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Long W, Foulds CE, Qin J, Liu J, Ding C, et al. ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012;122:1869–80.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, et al. Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol. 2011;25:2041–53.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mussi P, Yu C, O'Malley BW, Xu J. Stimulation of steroid receptor coactivator-3 (SRC-3) gene overexpression by a positive regulatory loop of E2F1 and SRC-3. Mol Endocrinol. 2006;20:3105–19.CrossRefPubMedGoogle Scholar
  14. 14.
    Liontos M, Niforou K, Velimezi G, Vougas K, Evangelou K, et al. Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas. Am J Pathol. 2009;175:376–91.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Jin R, Sun Y, Qi X, Zhang H, Zhang Y, et al. E2F1 is involved in DNA single-strand break repair through cell-cycle-dependent upregulation of XRCC1 expression. DNA Repair (Amst). 2011;10:926–33.CrossRefGoogle Scholar
  16. 16.
    Wu RC, Qin J, Yi P, Wong J, Tsai SY, et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell. 2004;15:937–49.CrossRefPubMedGoogle Scholar
  17. 17.
    Li S, Shang Y. Regulation of SRC family coactivators by post-translational modifications. Cell Signal. 2007;19:1101–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, et al. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell. 2006;124:381–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Wu RC, Feng Q, Lonard DM, O'Malley BW. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell. 2007;129:1125–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, et al. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006;66:9731–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Teh MT, Gemenetzidis E, Chaplin T, Young BD, Philpott MP. Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer. 2010;9:45.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Li Q, Zhang N, Jia Z, Le X, Dai B, et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009;69:3501–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 2005;25:10875–94.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Wang IC, Chen YJ, Hughes DE, Ackerson T, Major ML, et al. FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J Biol Chem. 2008;283:20770–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Shuo Geng
    • 1
  • Xiaoyu Wang
    • 1
  • Xiaoyan Xu
    • 1
  • Hepeng Zhang
    • 1
  • Yan Ma
    • 1
  • Yunqi Zhang
    • 1
  • Baoxin Li
    • 2
  • Zhenggang Bi
    • 1
  • Chenglin Yang
    • 1
  1. 1.Department of Orthopedic SurgeryThe First Affiliated Hospital of Harbin Medical UniversityNangang, HarbinChina
  2. 2.Department of PharmacologyHarbin Medical UniversityHarbinChina

Personalised recommendations